Phase 1 data in healthy volunteers and dystonia patients showed VIM0423 was safe and well-tolerated up to and exceeding target doses over 28 days CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE)-- ...

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

Sodium oxybate is the first oral treatment for laryngeal dystonia to show efficacy at providing temporary relief for debilitating symptoms that impact speaking, according to the results of a Mass Eye ...

Add Yahoo as a preferred source to see more of our stories on Google. When we think of movement disorders, the tremors associated with Parkinson’s disease are probably what first spring to mind.

Dystonia is a movement disorder that causes muscles to contract involuntarily, often leading to repetitive or twisting movements in different parts of the body. While the condition is not typically ...